Alta Sciences

AUGUST 29, 2024

The global market for CNS therapeutics is a multi-billion-dollar industry, and is projected to grow from $102.4 billion USD by 2028. As the body’s processing center, the CNS is responsible for all functions of our bodies, including thoughts, emotions, memories, and behaviors. billion USD in 2023 to $166.53

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

Alta Sciences

APRIL 5, 2024

Watch Altasciences in "Flipping the Drug Development Industry on Its Head" A Brief History of the CRO Market Contract Research Organizations (CROs) first entered the pharma world in the 1970s. As of 2023, Contract Pharma reported that the CRO market was estimated to be worth USD 76.6 billion by 2028—a CAGR growth rate of 10.7%

Drug Development 52

Drug Development Pharma Companies Marketing Drugs 52

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. Marketed as a gesture of scientific goodwill, it also gave the companies the benefit of further academic research into their models free of charge. Marketing agencies emerged to convince humanity to crave more than what evolution had granted them.

Engineering 141

Engineering Virus DNA Therapies 141

The Pharma Data

JUNE 2, 2023

Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2028, except upon the occurrence of an early release event provided for under Article R. 3324-22 of the French Labour Code and authorized in the subscriber’s country.

Regulations 52

Regulations Marketing 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. Each phase-in program requires the manufacturer to have had a Coverage Gap Discount Program agreement in effect in 2021, and only covers applicable drugs that have been in the market as of August 16, 2022 (i.e., Final Guidance at 2.

Compliance 105

Compliance Drugs Pharmacy Licensing 105

Agency IQ

JUNE 7, 2024

The PPPR framework governs the authorization, sale, and use of PPPs, establishing a pre-market approval process for active substances – the pesticide components which control pests, weeds, and plant diseases – and for synergists and safeners before they can be allowed for use in PPPs.

Regulations 40

Regulations Animal Testing Production Marketing 40

The Pharma Data

JANUARY 19, 2021

It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028. It is offering 70 million ordinary shares with a price between $20 and $23 per share. Ortho Clinical Diagnostics is a leader in in vitro diagnostics.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

NOVEMBER 8, 2020

Additionally, our pipeline and our recent transactions have significant mid-term value still to be unlocked that reinforces our potential in the market. Although the area of dermatology has been severely disrupted since the COVID-19 pandemic began, the EU market shows resilience and the US market is starting to show signs of recovery in Q3.

Licensing 52

Licensing Licensing Marketing Production 52

Agency IQ

MAY 28, 2024

This draft framework – which will come into force alongside the future medical device regulations – proposes four market access routes that have the potential to recognize the decision-making of four “comparable regulator countries,” but only for certain device and diagnostics types. law as the Medical Devices Regulation 2002 (UK MDR 2002).

International 40

International Regulations Licensing Licensing 40

FDA Law Blog: Biosimilars

OCTOBER 6, 2023

The practical consequence of adding these words is that LDTs are expressly defined as a type of IVD device, and subject to device regulations, including registration and listing, premarket review, post-market reporting, and quality system regulation. direct-to-consumer tests, tests for use in a public health emergency).

Laboratories 64

Laboratories FDA Regulations Production 64

The Premier Consulting Blog

NOVEMBER 20, 2023

Phase 5 (4 years after publication; no earlier than April 1, 2028) End of Enforcement Discretion for: Premarket review for moderate-risk and low-risk IVDs needing premarket review. Our expertise gives us the ability to develop customized and tailored strategic plans, mitigate regulatory risks, and optimize marketing success.

Laboratories 52

Laboratories FDA Clinical Development Regulations 52

The Pharma Data

JANUARY 25, 2021

Prior to November 1, 2028, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. This activity could increase (or reduce the size of any decrease in) the market price of the Company’s common stock, the notes or the Company’s 2.50% Convertible Senior Notes due 2027 at that time.

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52

Agency IQ

MAY 17, 2024

The Creating Hope Reauthorization Act would extend the expiration date of the program for another four years , from September 30, 2024 to September 30, 2028. focuses on marketing exclusivity periods granted to orphan drugs. 7383, Retaining Access and Restoring Exclusivity (RARE) Act This proposed bill , sponsored by Reps.

FDA 40

FDA Disease FDA Approval Production 40

Agency IQ

JUNE 28, 2024

New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. Sections 5 – 9 are labeled as Part A and cover clinical evaluation considerations.

Trials 40

Trials Marketing Clinical Trials Disease 40

Agency IQ

JANUARY 26, 2024

That trade association offered several possible solutions, including extending IVDR transition timelines, immediate deployment of the completed portions of EUDAMED, new regulatory options for orphan IVDs, the use of conditional certificates, and required reporting by manufacturers when they intend to remove an IVD from the European market.

Regulations 40

Regulations Compliance Laboratories Production 40

Agency IQ

MARCH 7, 2024

To keep critical devices and in vitro diagnostics (IVDs) available for patients in Great Britain (England, Scotland, and Wales), a much smaller market than the remaining 27 Member States of the E.U., government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. post-market regulation here.]

Regulations 40

Regulations International Production Government 40

The Pharma Data

JANUARY 9, 2021

We are proud to be a leader in the growing public health threat market, enabled by our development and manufacturing expertise, successful public-private partnerships, and broad portfolio of products and CDMO services. “Operationally, we rapidly responded to our customers’ needs, and financially, we delivered record revenue and earnings.

Government 40

Government Vaccine Production Licensing 40

Agency IQ

AUGUST 16, 2024

SPA allows sponsors to gain regulatory perspective on whether a proposed trial design is adequate to support a marketing application, though the ultimate approval decision is based on the data submitted for review. The study is planned to begin in 2026 and conclude in 2028.

FDA 40

FDA Trials Therapies Regulations 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 4, 2020

Amarin’s decision to continue to invest in expanding the market for VASCEPA also reflects its confidence in its manufacturing processes, which the company has built over a decade to achieve consistent, high-quality, stable supply to support anticipated global demand. commercial team.

Production 40

Production Trials FDA Disease 40

Agency IQ

OCTOBER 12, 2023

The Kigali Amendment created a timeline to reduce overall HFC use and consumption by 80-85% by the late 2040s, as well as HFC consumption level freezes in 2024 and 2028 for certain countries. These regulations would apply to HFCs and HFC alternatives that have lower flammability ratings and overall greater market value.

Regulations 40

Regulations Production International Marketing 40

Agency IQ

FEBRUARY 2, 2024

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. IVDs used in blood donation screening/processing). In the E.U.,

FDA 40

FDA Laboratories Regulations Production 40

Agency IQ

MARCH 29, 2024

EPA also proposed an additional set of CO2 standards for HD vehicles that would begin to apply in MY 2028, with progressively more stringent standards each model year through 2032. EPA plans to continue its outreach efforts with affected parties.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

DECEMBER 15, 2023

EPA also proposed an additional set of CO2 standards for HD vehicles that would begin to apply in MY 2028, with progressively more stringent standards each model year through 2032. Monitoring preparations are anticipated in 2027, with sample collection between 2028-2030 and reporting concluding in 2031.

Regulations 40

Regulations Compliance Production Government 40

FDA Law Blog: Biosimilars

JANUARY 2, 2025

The compliance date is February 25, 2028. FDA believes that such a standardized graphic will further support FDAs goal of helping consumers identify food products that can be the basis of healthy eating patterns consistent with the DGs. The final rule is effective 60 days from December 27, 2024, i.e., February 25, 2025.

FDA 52

FDA Production Science Compliance 52